রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন*
Indications:
LIJENTA-MX 5 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, especially in patients who benefit from extended-release metformin formulations.
Pharmacology:
Linagliptin is a DPP-4 inhibitor that enhances the body’s natural incretin system, promoting insulin release and decreasing glucagon levels. Metformin XR (Extended Release) reduces hepatic glucose production, improves peripheral glucose uptake, and has a slower release mechanism for sustained effect.
Dosage & Administration:
One tablet once or twice daily with meals, depending on patient response and physician recommendation. Extended-release tablets should be swallowed whole and not crushed or chewed.
Interaction:
May interact with other glucose-lowering agents, such as insulin or sulfonylureas, increasing the risk of hypoglycemia. Also interacts with diuretics, corticosteroids, and contrast agents. Monitor renal function and blood glucose regularly.
Contraindications:
Contraindicated in patients with renal impairment, metabolic acidosis, hypersensitivity to the ingredients, and acute conditions that may cause tissue hypoxia such as cardiac or respiratory failure.
Side Effects:
Common side effects include flatulence, diarrhea, nausea, and headache. Risk of lactic acidosis is rare but serious. Hypoglycemia may occur when combined with insulin or sulfonylureas.
Pregnancy & Lactation:
Use during pregnancy only if clearly needed. Caution advised during breastfeeding, as active ingredients may pass into breast milk.
Precautions & Warnings:
Regular monitoring of renal function is essential. Caution in patients with liver disease, alcohol abuse, or heart failure. Avoid use in dehydrated or acutely ill patients.
Therapeutic Class:
Combination Oral Hypoglycemics – DPP-4 Inhibitor & Extended-Release Biguanide
Storage Conditions:
Store below 30°C in a dry place, away from direct sunlight. Keep out of reach of children.